Groessl, MichaelTsybin, Yury O.Hartinger, Christian G.Keppler, Bernhard K.Dyson, Paul J.2010-06-072010-06-072010-06-07201010.1007/s00775-010-0635-0https://infoscience.epfl.ch/handle/20.500.14299/50663WOS:000278119200005The binding of the ruthenium-based anticancer drug candidates KP1019, NAMI-A and RAPTA-T towards different double-stranded oligonucleotides was probed by electrospray ionisation mass spectrometry and compared with that of the widely used platinum-based chemotherapeutics cisplatin, carboplatin and oxaliplatin. It was found that the extent of adduct formation decreased in the following order: cisplatin > oxaliplatin > NAMI-A > RAPTA-T > carboplatin > KP1019. In addition to the characterisation of the adducts formed with the DNA models, the binding sites of the metallodrugs on the oligonucleotides were elucidated employing top-down tandem mass spectrometry and were found to be similar for all the metallodrugs studied, irrespective of the sequence of the oligonucleotide. A strong preference for guanine residues was established.RutheniumPlatinumAnticancerOligonucleotidesMass spectrometryDouble-Stranded DnaAssisted-Laser-Desorption/IonizationIn-VitroPta ComplexesCross-LinksDrugsBindingChemotherapyCisplatinAdductstext::journal::journal article::research article